Bioivt, LLC

Bioivt, LLC, a for-profit limited liability company headquartered in Westbury, New York, supplies high-quality biological specimens and related research services to federal agencies as a prime contractor across 100 percent of its recent award footprint, competing full-and-open with no socioeconomic set-aside designations. The vendor operates through four named subsidiaries — Zen-Bio, Inc., Optivia Biotechnology, Inc., Fidelis Research EAD, and Xenotech LLC — that collectively serve federal research and medical readiness missions.

Bioivt's core offering is cryopreserved and cryoplateable hepatocytes (liver cells), plasma, serum, cerebrospinal fluid, urine, and other specialized biological specimens for pharmaceutical drug-metabolism testing, in-vitro assay support, and medical research. Representative prime work includes a $4.99 million single-award indefinite-delivery contract from the Defense Health Agency awarded in January 2026 for cynomolgus macaque and rhesus monkey cryoplateable hepatocytes and male and female human cryoplateable hepatocytes in support of Walter Reed Army Institute of Research through January 2031; a $218,520 single-award indefinite-delivery contract from Veterans Integrated Service Network 23 awarded in September 2025 for pre-trial Alzheimer's drug testing services including cytochrome P450 enzyme inhibition studies and transporter interaction assessments, running through September 2027; and a one billion dollar blanket purchase agreement with the National Institutes of Health Office of Logistics and Acquisition Operations established in May 2023 for on-demand supply of biological materials and blood products, valid through January 2027. Other recent examples include a $183,092 purchase order from the National Center for Advancing Translational Sciences in September 2024 for a transporter substrate assessment study, a $71,960 purchase order from CDC Pittsburgh in September 2024 for serum for Oropouche virus response, and a $33,510 purchase order from the FDA in July 2026 for metabolism-qualified cryopreserved human hepatocytes.

Customer concentration tilts heavily toward defense and medical research agencies. The Defense Health Agency leads by both award count and dollar value with 11 awards totaling $5.3 million in combined potential value, followed by the Department of the Army Medical Command with 7 awards and $4 million in potential value. The top five customer agencies account for 57 percent of award count and 90 percent of combined potential value. The NIH ecosystem — spanning the National Center for Advancing Translational Sciences, the National Institute of Allergy and Infectious Diseases, and the National Institute of Diabetes and Digestive and Kidney Diseases — collectively represents the second-largest customer grouping by count and accounts for sustained volume across smaller purchase orders. Bioivt's vehicle footprint centers on two indefinite-delivery contracts: the Army Medical Command's W81XWH21D0004 with 15 task orders totaling $667 thousand in combined potential value, and Veterans Integrated Service Network 23's contract 36C24E25D0036 with 1 task order of $162 thousand. The NIH blanket purchase agreement, despite its one billion dollar ceiling, does not report task-order counts in the vehicle-usage block, indicating episodic ordering rather than a sustained volume stream.

Bioivt's award activity has been episodic rather than growth-oriented. Annual prime-award counts declined from 11 in 2024 to 6 in 2025 and 3 through August 2026, reflecting a transactional supply relationship with federal customers rather than expansion of contract base. Combined potential value across all 70 prime awards stands at $11.7 million, with only 24 percent obligated as of the summary date — consistent with firm fixed-price purchase orders and delivery orders issued individually rather than as blanket releases against standing vehicles. Only 2 awards face ultimate completion within the next twenty-four months, with combined potential value of $54 thousand, indicating minimal recompete exposure in that window but also minimal pipeline maturity into 2027. Award concentration by NAICS reflects Bioivt's manufacturing posture: 49 awards fall under Biological Product Manufacturing, 7 under Testing Laboratories and Services, and 6 under In-Vitro Diagnostic Substance Manufacturing. Bioivt operates entirely as a prime contractor across its visible federal footprint, with no subcontract activity reported in the source, positioning it as a sole-source or preferred supplier of specialized biological materials rather than a systems integrator or teaming vehicle.